Home Banking THIS PENNY STOCK IS ABOUT TO GET FDA APPROVAL!

THIS PENNY STOCK IS ABOUT TO GET FDA APPROVAL!

by smart

it feels good to be right what’s happening investors welcome back to another video this video is for entertainment purposes only and in this video we are speaking about sense and bio ticker symbol s-e-s-n this isn’t a sense video okay it’s not a typo this is a different company but if you clicked here looking for sends and you’ve stumbled across censor and why not just watch this video because there is a lot of potential in this company in my opinion and when you see what they do i think you might just like it before we begin though to those new to the channel my name is dean i am not a financial advisor and this is not financial advice it is for entertainment purposes only i’m just someone who loves researching and investing in stocks because i want to make as much money as possible in the stock market to retire early and i thought hey since i’m doing this research investing in these stocks anyway why not make some videos put them out there on youtube and maybe help some of you also and all i ask in return is that you please invest in that like button and add the subscribe button to your portfolio let’s try to get this video to 100 likes if each and every one of you yes i’m speaking to you if you like this video you will help me get to that goal so it would really help me out with that wasting any more time let’s get straight into the video since then bio has had a nice run up over the past five days and this is something we predicted i made a video talking about a catalyst that this stock had coming up and i said i can see this causing a whole heap of green and it has we are up seven percent for the week and what was the big news what was the big catalyst well sense and bio announces productive late cycle meeting with the fda for vicinium if you don’t know about the company you don’t know about vicinian stick around i will explain it in a minute but first let’s just talk about this catalyst right here so the late cycle meeting was held and it is a review process between the members of the fda and the team and the applicant to discuss the status of the review and the results were good we are pleased with the outcome of the late cycle meeting and continue to feel encouraged by the level of engagement from the fda in our ongoing discussions regarding the bla for vicinium if you’re confused it will all make sense in a minute as you can see this news came out on the 14th and since then the stock is up 8 what was interesting was we did see a bit of a dip here at the beginning however we did see a run-up now another thing to consider is this price action here it has been in line with the market if we look at stocks like send stock b ngo stock ndm stock we have seen this similar run up here however we can’t deny the fact that this was a big catalyst and there’s many more in the pipeline for this company okay when you see what they do when you look at the competition and you compare the companies it is hard to not see a massive potential for sense and bio sense and bio is a company that is committed to saving and improving the lives of patients with cancer we are a late stage clinical company advanced targeting fusion protein therapies for the treatment of patients with cancer our lead program vicinium is currently in the follow-up stage of a phase three registration trial for the treatment of bcg unresponsive non-muscle invasive bladder cancer in february 2021 the fda accepted for filing sense and bios boa for the cinema and the treatment of the bcb unresponsive nmibc what a mouthful that is and granted the application priority review with the targeted pdufa date of august 18 2021 massive catalyst okay that’s the date that they’re hopefully getting the approval that is a huge catalyst for this company and it is just around the corner that is not that far whatsoever and sense and bio retains worldwide rights to vicinium with the exception of greater china and the middle east and north africa for which the company has partnered with chile pharmaceutical and jicama pharmaceuticals respectively for commercialization so that is a brief idea of what the company does off their about us page so their june 2021 business update i just want to go over some a few slides here not too many just a few slides of their investor presentation vicinium has the potential to improve patient outcomes while reducing overall healthcare costs massive benefit there clear regulatory path for potential approval in the us 2021 in europe 2022 the citium has the potential to be best in class with projected global peak revenue of one to three billion dollars what’s crazy is they’re saying there they have the potential to be the best in class which is huge for any company and their projected revenue of one to three billion dollars urologists play a key role throughout the patient journey the reason why i’ve highlighted this point here is because this this vicinium product here from i made a video on it in the past i made a very detailed video on this company i would highly recommend you watch it i’ll leave it at the end of this one but what this product here this therapy is it’s administered and given by the doctor by the urologist rather now why this is interesting is because the other treatments that treat this disease okay the other treatments that treat this disease are actually have to be given in another clinic out of the urologist clinic which means the urologist loses that patient not only as a mental emotional connection that they have they’re trying to help the patient but also financially because with this treatment the urologist gives the patient the treatment the treatment keeps coming back it means more revenue for the clinic and this is very very interesting because i believe it was eighty percent we said in my last video eighty percent of the urologists that prescribe the most amount of these bladder treatments agreed that they would rather prescribe the cinema so that’s why they mean when they say best in class so their brand strategy is to like we just mentioned position vicini and best in class they want to have a u.s market leadership in late 2022 so late next year they want to be in the us they want to be the market leader and they have as we said peak global sales of 1 billion to 3 billion dollars what is crazy about that is this company currently has a market cap of 715 million dollars so they’re saying on the low end on their low end their revenue their sales is going to be more than the market cap of the company it tells me as someone who’s looking to invest in this company that there is a lot of potential growth here because how often do you see a market cap less than the sales of a company not very often i haven’t found many companies that have that and it just tells me that this company is very very cheap providing we’re able to execute and hit these numbers i need to stress this out right now this is high risk okay it is a penny stock anything can happen so please don’t invest more than you’re willing to lose this is a long term investment consider averaging in and do your own research because i am not a financial advisor now just before we jump into another catalyst that has just happened for this company more good news i just want to quickly go over their recent financial highlights and we can see that in q1 of 2021 they have cash and cash equivalents of 110 million dollars a stock price of 2.60 doesn’t really matter market cap of 447 million no outstanding depth so pretty decent what was their recent catalyst well sense and bio and cooler pharmaceutical announced its enrollment of first patient in clinical trial for the cenium in china the enrollment of the first patient in the clinical trial in china is a significant milestone in realizing our mission to save and improve the lives of patients globally queerly pharmaceutical has a strong clinical and regulatory experience and we are encouraged by the speed of which quilly pharmaceutical is moving forward with its clinical stage and regulatory efforts we look forward to working closely with quilley pharmaceutical in the coming months as we continue to make progress in bringing the cinema to the market in china so we have a lot of big catalysts coming up for this company we’ve got them bringing their vicinium in the market in china okay we have the fda approval august 18th not that far away whatsoever and we also have of course earnings you know that’s something to keep an eye out for so i will definitely be keeping an eye on this company i will continue to cover them on this channel so if you haven’t done so already make sure you subscribe make sure your notifications are turned on and let me know in the comments below are you looking to invest in this company do you see the potential that i’m seeing here let me know what are your price targets thank you so much for watching guys and i will see you all in the next video


rn
THIS PENNY STOCK IS ABOUT TO GET FDA APPROVAL!
rn

Related Posts

Leave a Comment